Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| See historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Nov 20 | 20 DMA Support | Bullish | 0.00% |
| Nov 16 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.94% |
| Nov 16 | Pocket Pivot | Bullish Swing Setup | -0.94% |
| Nov 16 | Narrow Range Bar | Range Contraction | -0.94% |
| Nov 16 | NR7 | Range Contraction | -0.94% |
| Nov 16 | NR7-2 | Range Contraction | -0.94% |
| Nov 16 | Inside Day | Range Contraction | -0.94% |
| Nov 16 | Up 3 Days in a Row | Strength | -0.94% |
| Nov 16 | Up 4 Days in a Row | Strength | -0.94% |
| Nov 15 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.93% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-12
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BGNE news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 220.1 |
| 52 Week Low | 77.54 |
| Average Volume | 420,208 |
| 200-Day Moving Average | 160.9111 |
| 50-Day Moving Average | 138.5486 |
| 20-Day Moving Average | 120.715 |
| 10-Day Moving Average | 122.492 |
| Average True Range | 7.6478 |
| ADX | 22.27 |
| +DI | 18.9406 |
| -DI | 23.7128 |
| Chandelier Exit (Long, 3 ATRs ) | 114.4566 |
| Chandelier Exit (Short, 3 ATRs ) | 128.1334 |
| Upper Bollinger Band | 134.9378 |
| Lower Bollinger Band | 106.4922 |
| Percent B (%b) | 0.68 |
| BandWidth | 23.564263 |
| MACD Line | -2.9885 |
| MACD Signal Line | -4.9771 |
| MACD Histogram | 1.9885 |
| Fundamentals | Value |
|---|---|
| Market Cap | 5.01 Billion |
| Num Shares | 39.8 Million |
| EPS | -4.97 |
| Price-to-Earnings (P/E) Ratio | -25.32 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 12.46 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 135.93 | ||||
| Resistance 3 (R3) | 135.22 | 131.13 | 134.25 | ||
| Resistance 2 (R2) | 131.13 | 128.56 | 131.49 | 133.68 | |
| Resistance 1 (R1) | 128.48 | 126.97 | 129.81 | 129.19 | 133.12 |
| Pivot Point | 124.39 | 124.39 | 125.06 | 124.75 | 124.39 |
| Support 1 (S1) | 121.74 | 121.82 | 123.07 | 122.45 | 118.52 |
| Support 2 (S2) | 117.65 | 120.23 | 118.01 | 117.96 | |
| Support 3 (S3) | 115.00 | 117.65 | 117.40 | ||
| Support 4 (S4) | 115.71 |
